ArticleAACE endocrinology and diabetes
Sulpiride-Induced Severe Hyperprolactinemia in an IBS Patient: A Case Report From Saudi Arabia.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This case report highlights a significant instance of severe hyperprolactinemia induced by Sulpiride in a patient with irritable bowel syndrome. While Sulpiride is sometimes used off-label for gastrointestinal issues due to its prokinetic and anxiolytic effects, its potential to markedly raise serum prolactin levels is often overlooked, especially in the Middle Eastern population. This report adds valuable regional insights to the limited global literature on this adverse drug reaction. Case Description: A 38-year-old female from Saudi Arabia with irritable bowel syndrome presented with galactorrhea, irregular menstrual cycles, and breast tenderness after 1 month of taking sulpiride 50 mg daily for gastrointestinal issues. She reported no prior endocrinology or gynecology problems. Discussion: Laboratory investigations showed a marked elevation in serum prolactin levels, exceeding 200 ng/mL. Imaging examinations verified the absence of any pituitary tumor. Sulpiride was discontinued, and after 2 weeks, a follow-up assessment showed that prolactin levels had returned to normal, and the symptoms had resolved. Conclusion: Monitoring hyperprolactinemia is critical in patients receiving Sulpiride, especially when prescribed for nonpsychiatric cases like irritable bowel syndrome. Regular checks and cautious off-label prescribing are crucial for prompt identification and discontinuation of the medication to prevent long-term endocrine issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.